Epstein-barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders

Pathobiology

Volumn 80, Issue 2, 2012, Pages 53-59

  Ghigna, Maria Rosa ^a   Reineke, Tanja ^f   Rincé, Patricia ^b   Schüffler, Peter ^g   El McHichi, Bouchra ^b   Fabre, Monique ^a   Jacquemin, Emmanuel ^c   Durrbach, Antoine ^d   Samuel, Didier ^e   Joab, Irène ^f   Guettier, Catherine ^a   Lucioni, Marco ^h   Paulli, Marco ^h   Tinguely, Marianne ^f   Raphael, Martine ^b  

^a HÔPITAL PAUL BROUSSE   (France)

^b UMR 8126   (France)

^c Pediatric Hepatology Unit   (France)

^d BICÊTRE HOSPITAL   (France)

^e INSERM   (France)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g ETH ZURICH   (Switzerland)

^h UNIVERSITY OF PAVIA   (Italy)

Author keywords

Apoptosis; Epstein Barr virus; Posttransplant lymphoproliferative disorders; Transplantation

Indexed keywords

BIM PROTEIN; CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; PUMA PROTEIN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CHILD; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SCHOOL CHILD; UPREGULATION; VIRUS CELL INTERACTION; VIRUS SURVIVAL;

ADOLESCENT; ADULT; AGED; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; VIRUS LATENCY; YOUNG ADULT;

HUMAN HERPESVIRUS 4;

EID: 84864515135     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000339722     Document Type: Article

References (35)

1. Knowles DM, Cesarman E, Chadburn A, et al: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.
2. Knowles DM: Immunodeficiency-Associated lymphoproliferative disorders. Mod Pathol 1999; 12: 200-217. (Pubitemid 29093902)
3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, ed 4. Lyon, IARC, 2008.
4. Locker J, Nalesnik M: Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 1989; 135: 977-987. (Pubitemid 20026518)
5. Wilkinson AH, Smith JL, Hunsicker LG, et al: Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989; 47: 293-296. (Pubitemid 19069708)
6. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728.
7. Armitage JM, Kormos RL, Stuart RS, et al: Posttransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877-886, discussion 886-877.
8. Leblond V, Davi F, Charlotte F, et al: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 1998; 16: 2052-2059. (Pubitemid 28265040)
9. Rowe M, Niedobitek G, Young LS: Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders. Springer Semin Immunopathol 1998; 20: 389-403. (Pubitemid 28550107)
10. Trappe R, Oertel S, Leblond V, et al: Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-Cell posttransplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206.
11. Krauer KG, Burgess A, Buck M, Flanagan J, Sculley TB, Gabrielli B: The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 2004; 23: 1342-1353. (Pubitemid 38406830)
12. O'Nions J, Allday MJ: Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2. Oncogene 2003; 22: 7181-7191. (Pubitemid 37378550)
13. Young L, Alfieri C, Hennessy K, et al: Expression of Epstein-Barr virus transformation-Associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989; 321: 1080-1085. (Pubitemid 19256661)
14. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR: The BCL-2 family reunion. Mol Cell 2010; 37: 299-310.
15. Gillissen B, Essmann F, Hemmati PG, et al: Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. J Cell Biol 2007; 179: 701-715. (Pubitemid 350146256)
16. Huang DC, Strasser A: BH3-Only proteinsessential initiators of apoptotic cell death. Cell 2000; 103: 839-842.
17. Giam M, Huang DC, Bouillet P: BH3-only proteins and their roles in programmed cell death. Oncogene 2008; 27(SUPPL1):S128-S136.
18. Letai A: BH3 domains as BCL-2 inhibitors: Prototype cancer therapeutics. Expert Opin Biol Ther 2003; 3: 293-304. (Pubitemid 36458760)
19. Hildeman DA, Zhu Y, Mitchell TC, et al: Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity. 2002; 16: 759-767. (Pubitemid 34786475)
20. Strasser A: The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005; 5: 189-200. (Pubitemid 40364821)
21. Clybouw C, McHichi B, Mouhamad S, et al: EBV infection of human B lymphocytes leads to down-regulation of Bim expression: Relationship to resistance to apoptosis. J Immunol 2005; 175: 2968-2973. (Pubitemid 41170514)
22. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K: MicroRNA-17-92 down-regulates expression of distinct targets in different B-Cell lymphoma subtypes. Blood 2009; 113: 396-402.
23. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ: Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. Plos Pathog 2009; 5:e1000492.
24. Pinon JD, Labi V, Egle A, Villunger A: Bim and Bmf in tissue homeostasis and malignant disease. Oncogene. 2008; 27(SUPPL1):S41-S52.
25. Dunkle A, Dzhagalov I, He YW: Mcl-1 promotes survival of thymocytes by inhibition of Bak in a pathway separate from Bcl-2. Cell Death Differ 2010; 17: 994-1002.
26. Dutta S, Gulla S, Chen TS, Fire E, Grant RA, Keating AE: Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL. J Mol Biol 2010; 398: 747-762.
27. Han J, Goldstein LA, Gastman BR, Rabinovitz A, Rabinowich H: Disruption of Mcl-1. Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem 2005; 280: 16383-16392. (Pubitemid 40616768)
28. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ: Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003; 426: 671-676. (Pubitemid 38009376)
29. Bernstein C, Bernstein H, Payne CM, Garewal H: DNA repair/pro-Apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis. Mutat Res 2002; 511: 145-178. (Pubitemid 34621252)
30. Schreiber V, Dantzer F, Ame JC, de Murcia G: Poly(ADP-ribose): Novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517-528. (Pubitemid 44036457)
31. Murray PG, Swinnen LJ, Constandinou CM, et al: BCL-2 but not its Epstein-Barr virusencoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 1996; 87: 706-711. (Pubitemid 26030326)
32. Camilleri-Broet S, Camparo P, Mokhtari K, et al: Overexpression of BCL-2, BCL-X, and BAX in primary central nervous system lymphomas that occur in immunosuppressed patients. Mod Pathol 2000; 13: 158-165. (Pubitemid 30109103)
33. Loomis R, Carbone R, Reiss M, Lacy J: Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-Associated lymphoproliferative disease to rituximab. Clin Cancer Res 2003; 9: 1931-1939. (Pubitemid 36554622)
34. Masood A, Azmi AS, Mohammad RM: Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy. Cancers (Basel) 2011; 3: 1527-1549.
35. Brem EA, Thudium K, Khubchandani S, et al: Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol 2011; 153: 599-611.